On a preliminary basis, Coherus BioSciences (CHRS -0.4%) expects Q1 product sales of $115.0M – 117.5M, up 213% (midpoint) from a year ago, but a bit short of $118.6M consensus.
Net income should be $33.5M – 38.0M, reflecting modest headwinds from the COVID-19.
Management says disruptions to its operations from
the coronavirus pandemic should be transient with the greatest impact
coinciding with the contagion’s peak effect on the U.S. medical system
and personal behaviors.
https://seekingalpha.com/news/3560135-coherus-bio-sees-q1-product-sales-shy-of-consensus
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.